IGF-1 LR3
Sourcing GuideSourcing IGF-1 LR3 from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.
Key Takeaways
Procurement lens: IGF-1 LR3 sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 9111 Da. Mechanism: Binds the IGF-1 receptor with full agonist activity. Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days. Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger). Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.
Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. Sourcing implications: the mechanism dictates which analytical assays are appropriate for QC, which storage conditions preserve activity, and which reconstitution and use practices matter. The subsections below cover HPLC and analytical identity, COA evaluation and red flags, reconstitution and storage, and vendor tier comparison for IGF-1 LR3.
COA evaluation and red flags
Acceptable IGF-1 LR3 certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.
HPLC purity and analytical identity
Minimum acceptable HPLC purity for IGF-1 LR3 is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 9111 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.
Vendor tier comparison and price discipline
Three vendor tiers operate in the IGF-1 LR3 market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.
Pharmaceutical-grade compounded IGF-1 LR3 is the lowest-risk sourcing path for reconstitution guide use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
For users targeting vendor comparison, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.
Sourcing IGF-1 LR3 for regulatory sourcing use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.
Pharmaceutical-grade compounded IGF-1 LR3 is the lowest-risk sourcing path for storage protocol use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 20-50 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 12-50 mcg | 4–6 weeks initial cycle |
| Sourcing Guide focus | SubQ | 20-50 mcg | 1-2x daily SubQ |
| Maintenance phase | SubQ | 14-50 mcg | Ongoing with periodic pauses |
Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.
- IGF-1 LR3 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with IGF-1 LR3's mechanism in sourcing / quality / procurement protocols.
- IGF-1 LR3 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with IGF-1 LR3's mechanism in sourcing / quality / procurement protocols.
- IGF-1 LR3 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with IGF-1 LR3's mechanism in sourcing / quality / procurement protocols.
- IGF-1 LR3 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with IGF-1 LR3's mechanism in sourcing / quality / procurement protocols.
Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.
Lens-specific safety considerations for sourcing / quality / procurement use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| IGF-1 LR3 | Modified insulin-like growth factor 1 | ~20-30 hr (vs ~10 min for native IGF-1) | Sourcing Guide |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Lot variability across orders?
Visual quality inspection?
What should I check on a IGF-1 LR3 COA?
Vendor red flags?
What does IGF-1 LR3 stack well with?
How does IGF-1 LR3's half-life affect dosing?
Start a IGF-1 LR3 Protocol
Alukard provides GMP-certified physician-supervised sourcing with GMP-certified IGF-1 LR3 and Pharmaceutical-grade compounds with full COA documentation.
Get ProtocolQuick Facts
- Molecular weight
- 9111 Da
- Sequence length
- 83 aa
- Half-life
- ~20-30 hr (vs ~10 min for native IGF-1)
- WADA
- Banned (S2)
- FDA
- Unapproved (research reagent)
- Research
- Animal models; off-label use widespread
Stack Partners
All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Sourcing / Quality / Procurement Protocol for IGF-1 LR3
Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.
HIPAA Compliant · GMP Certified · Physician Supervised